Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women`s health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company`s biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss...
Website: organon.com



Growth: Pretty weak revenue growth rate 5.5%, there is acceleration compared to average historical growth rates -4.6%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is positive, +20.2%. On average the margin is decreasing unsteadily. Gross margin is high, +59.0%. In the last quarter the company did not beat the estimated EPS, -6.9%. The company was ahead of estimated EPS in 50% of quarters (showing a gain of +$0.04 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 5.1%. Free cash flow yield 0.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 99.5% higher than minimum and 44.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.4x by EV / Sales multiple , the company can be >100% undervalued

Key Financials (Download financials)

Ticker: OGN
Share price, USD:  (+0.4%)21.85
year average price 17.71  


year start price 20.12 2023-05-24

max close price 23.77 2023-08-08

min close price 10.95 2023-11-16

current price 21.85 2024-05-22
Common stocks: 255 695 000

Dividend Yield:  5.1%
EV / LTM EBITDA: 4.4x
EV / EBITDA annualized: 3.7x
Last revenue growth (y/y):  5.5%
Last growth of EBITDA (y/y):  -1.5%
Historical revenue growth:  -4.6%
Historical growth of EBITDA:  -17.0%
EV / Sales: 0.9x
Margin (EBITDA LTM / Revenue): 20.2%
Fundamental value created in LTM:
Market Cap ($m): 5 587
Net Debt ($m): 0
EV (Enterprise Value): 5 587
Price to Book: 116.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-05-14Zacks Investment Research

Surging Earnings Estimates Signal Upside for Organon (OGN) Stock

2024-05-11Seeking Alpha

Organon Graduates From Spinoff Skepticism, With A Yield Above 5%

2024-05-02Zacks Investment Research

What Makes Organon (OGN) a New Buy Stock

2024-05-02Zacks Investment Research

Organon (OGN) Tops Q1 Earnings and Revenue Estimates

2024-05-01Zacks Investment Research

Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store?

2024-04-29Zacks Investment Research

Stay Ahead of the Game With Organon (OGN) Q1 Earnings: Wall Street's Insights on Key Metrics

2024-04-25Zacks Investment Research

Earnings Preview: Organon (OGN) Q1 Earnings Expected to Decline

2024-04-24Zacks Investment Research

Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing

2024-04-22Zacks Investment Research

Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know

2024-04-15Zacks Investment Research

Organon (OGN) Advances While Market Declines: Some Information for Investors
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2022 q1 2021 q4 2021 q3 2021 q2 2021 q1 2020 q4 2020 q3 2020 q2 2020 q1
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31
symbol OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-03 2024-02-26 2023-11-03 2023-08-09 2023-05-05 2023-02-27 2022-11-04 2022-08-05 2022-05-06 2022-03-21 2021-11-12 2021-08-16 2021-06-21 2020-12-31 2020-09-30 2020-06-30 2020-03-31
acceptedDate 2024-05-03 08:10:28 2024-02-26 08:10:46 2023-11-03 07:52:59 2023-08-09 08:39:59 2023-05-04 18:40:01 2023-02-27 07:47:13 2022-11-03 17:58:50 2022-08-04 18:02:03 2022-05-05 21:16:53 2022-03-21 08:27:29 2021-11-12 16:52:11 2021-08-16 08:20:13 2021-06-21 08:16:50 2020-12-30 19:00:00 2020-09-29 20:00:00 2020-06-29 20:00:00 2020-03-30 20:00:00
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000 2022.000 2021.000 2021.000 2021.000 2021.000 2020.000 2020.000 2020.000 2020.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
revenue 1 622M 1 598M 1 519M 1 608M 1 538M 1 485M 1 537M 1 585M 1 567M 1 603M 1 600M 1 595M 1 506M 3 177M 1 613M 1 526M 1 780M
costOfRevenue 665M 683M 612M 640M 580M 594M 551M 588M 561M 599M 609M 583M 591M 1 814M 535M 460M 538M
grossProfit 957M 915M 907M 968M 958M 891M 986M 997M 1 006M 1 004M 991M 1 012M 915M 1 363M 1 078M 1 066M 1 242M
grossProfitRatio 0.590 0.573 0.597 0.602 0.623 0.600 0.642 0.629 0.642 0.626 0.619 0.634 0.608 0.429 0.668 0.699 0.698
researchAndDevelopmentExpenses 112M 134M 137M 128M 129M 142M 127M 106M 96M 189M 111M 76M 67M 154M 54M 51M 45M
generalAndAdministrativeExpenses 0 260M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 209M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 431M 469M 538M 451M 435M 470M 440M 423M 371M 482M 388M 416M 382M 744M 321M 284M 317M
otherExpenses -3M -4M -4M -1 000 000 -6M 0 0 0 0 0 0 0 0 0 0 0 0
operatingExpenses 543M 603M 675M 579M 564M 612M 567M 529M 467M 671M 499M 492M 449M 898M 375M 335M 362M
costAndExpenses 1 208M 1 286M 1 287M 1 219M 1 144M 1 206M 1 118M 1 117M 1 028M 1 270M 1 108M 1 075M 1 040M 2 712M 910M 795M 900M
interestIncome 0 -398M 134M 0 0 0 0 0 0 0 0 0 0 0 0 0 0
interestExpense 131M 129M 134M 132M 132M 119M 108M 98M 97M 98M 98M 62M 0 0 0 0 0
depreciationAndAmortization 65M 58M 228M 388M 57M 52M 57M 50M 53M 62M 52M 43M 38M 50M 40M 34M 33M
ebitda 479M 370M 228M 388M 388M 279M 415M 482M 539M 396M 539M 538M 509M 591M 708M 692M 846M
ebitdaratio 0.295 0.232 0.150 0.241 0.252 0.188 0.270 0.304 0.344 0.247 0.337 0.337 0.338 0.186 0.439 0.453 0.475
operatingIncome 414M 312M 232 000 389 000 331M 227M 358M 432M 486M 334M 492M 520M 466M 465M 703M 731M 880M
operatingIncomeRatio 0.255 0.195 0.000 0.000 0.215 0.153 0.233 0.273 0.310 0.208 0.308 0.326 0.309 0.146 0.436 0.479 0.494
totalOtherIncomeExpensesNet -178M -208M -18M -3M -96M -116M -76M -145M -44M -98M -103M -83M 1 000 000 -12M -22M -29M -36M
incomeBeforeTax 236M 104M 80M 254M 235M 111M 282M 287M 442M 236M 389M 437M 467M 453M 681M 702M 844M
incomeBeforeTaxRatio 0.145 0.065 0.053 0.158 0.153 0.075 0.183 0.181 0.282 0.147 0.243 0.274 0.310 0.143 0.422 0.460 0.474
incomeTaxExpense 35M -442M 22M 12M 58M 3M 55M 53M 94M 34M 66M 6M 72M 173M 121M 116M 110M
netIncome 201M 546M 58M 242M 177M 108M 227M 234M 348M 202M 323M 427M 399M 368M 547M 542M 703M
netIncomeRatio 0.124 0.342 0.038 0.150 0.115 0.073 0.148 0.148 0.222 0.126 0.202 0.268 0.265 0.116 0.339 0.355 0.395
eps 0.790 2.140 0.230 0.950 0.700 0.420 0.890 0.920 1.370 0.800 1.270 1.680 1.576 1.450 2.161 2.141 2.777
epsdiluted 0.780 2.130 0.230 0.950 0.690 0.420 0.890 0.920 1.360 0.790 1.270 1.680 1.576 1.450 2.161 2.141 2.777
weightedAverageShsOut 256M 256M 256M 255M 254M 254M 254M 254M 254M 254M 254M 254M 253M 253M 253M 253M 253M
weightedAverageShsOutDil 258M 257M 256M 256M 256M 255M 255M 255M 255M 255M 254M 254M 253M 253M 253M 253M 253M
link Link Link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2022 q1 2021 q4 2021 q3 2021 q2 2021 q1 2020 q4
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31
symbol OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-03 2024-02-26 2023-11-03 2023-08-09 2023-05-05 2023-02-27 2022-11-04 2022-08-05 2022-05-06 2022-03-21 2021-11-12 2021-08-16 2021-06-21 2020-12-31
acceptedDate 2024-05-03 08:10:28 2024-02-26 08:10:46 2023-11-03 07:52:59 2023-08-09 08:39:59 2023-05-04 18:40:01 2023-02-27 07:47:13 2022-11-03 17:58:50 2022-08-04 18:02:03 2022-05-05 21:16:53 2022-03-21 08:27:29 2021-11-12 16:52:11 2021-08-16 08:20:13 2021-06-21 08:16:50 2020-12-30 19:00:00
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000 2022.000 2021.000 2021.000 2021.000 2021.000 2020.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4
cashAndCashEquivalents 575M 693M 414M 326M 459M 706M 499M 545M 694M 737M 1 008M 730M 141M 500M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 575M 693M 414M 326M 459M 706M 499M 545M 694M 737M 1 008M 730M 141M 500M
netReceivables 1 556M 1 744M 1 648M 1 672M 1 445M 1 475M 1 440M 1 490M 1 322M 1 382M 1 498M 1 507M 1 010M 1 092M
inventory 1 263M 1 315M 1 186M 1 199M 1 121M 1 003M 879M 950M 946M 915M 918M 871M 924M 913M
otherCurrentAssets 802M 756M 802M 761M 755M 747M 774M 789M 757M 726M 905M 803M 902M 929M
totalCurrentAssets 4 196M 4 508M 4 050M 3 958M 3 780M 3 931M 3 592M 3 774M 3 719M 3 760M 4 329M 3 911M 2 977M 3 434M
propertyPlantEquipmentNet 1 180M 1 183M 1 096M 1 110M 1 055M 1 018M 906M 952M 970M 973M 967M 976M 986M 984M
goodwill 4 603M 4 603M 4 603M 4 603M 4 603M 4 603M 4 603M 4 603M 4 603M 4 603M 4 603M 4 603M 4 603M 4 603M
intangibleAssets 718M 533M 561M 592M 621M 649M 670M 638M 665M 651M 683M 711M 482M 503M
goodwillAndIntangibleAssets 5 321M 5 136M 5 164M 5 195M 5 224M 5 252M 5 273M 5 241M 5 268M 5 254M 5 286M 5 314M 5 085M 5 106M
longTermInvestments 5 316M -808M 0 -32 000 0 0 0 0 0 0 0 0 0 0
taxAssets 44 000 808M 43M 32 000 30M 0 43M 23M 0 0 0 0 0 0
otherNonCurrentAssets -4 122M 1 231M 659M 716M 674M 754M 623M 624M 640M 694M 753M 707M 594M 910M
totalNonCurrentAssets 7 695M 7 550M 6 962M 7 021M 6 983M 7 024M 6 845M 6 840M 6 878M 6 921M 7 006M 6 997M 6 665M 7 000M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 11 891M 12 058M 11 012M 10 979M 10 763M 10 955M 10 437M 10 614M 10 597M 10 681M 11 335M 10 908M 9 642M 10 434M
accountPayables 955M 1 314M 1 067M 1 115M 996M 1 132M 1 028M 1 130M 1 081M 1 382M 1 673M 1 812M 264M 259M
shortTermDebt 9M 9M 8M 8M 8M 8M 8M 9M 9M 9M 39M 39M 1 520M 0
taxPayables 196M 206M 161M 163M 192M 184M 217M 211M 202M 185M 335M 218M 288M 109M
deferredRevenue 196 000 0 161M 163 000 0 19M 43M 23M 0 0 0 0 0 0
otherCurrentLiabilities 1 581M 1 595M 1 255M 1 264M 1 342M 1 353M 1 249M 1 234M 1 216M 1 206M 1 082M 906M 803M 833M
totalCurrentLiabilities 2 545M 2 918M 2 491M 2 387M 2 346M 2 512M 2 328M 2 396M 2 306M 2 597M 3 129M 2 975M 2 875M 1 201M
longTermDebt 8 705M 8 751M 8 646M 8 722M 8 703M 8 905M 8 691M 8 884M 9 085M 9 125M 9 259M 9 309M 0 0
deferredRevenueNonCurrent 0 0 -43M 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 44M 47M 43M 32M 30M 19M 43M 23M 2M 4M 59M 71M 125M 121M
otherNonCurrentLiabilities 549M 412M 464M 393M 421M 411M 441M 448M 454M 463M 506M 487M 1 920M 9 932M
totalNonCurrentLiabilities 9 298M 9 210M 9 110M 9 147M 9 154M 9 335M 9 175M 9 355M 9 541M 9 592M 9 824M 9 867M 2 045M 10 053M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 125M 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilities 11 843M 12 128M 11 601M 11 534M 11 500M 11 847M 11 503M 11 751M 11 847M 12 189M 12 953M 12 842M 4 920M 11 254M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 3M 3M 3M 3M 3M 3M 3M 3M 3M 3M 3M 3M 0 3M
retainedEarnings 573M 443M -16M -25M -206M -331M -383M -551M -724M -998M -1 128M -1 473M 0 -219M
accumulatedOtherComprehensiveIncomeLoss -577M -541M -576M -533M -534M -564M -686M -589M -529M -513M -493M -464M -689M -604M
othertotalStockholdersEquity 49M 25M 0 0 0 0 0 0 0 0 0 0 5 411M 0
totalStockholdersEquity 48M -70M -589M -555M -737M -892M -1 066M -1 137M -1 250M -1 508M -1 618M -1 934M 4 722M -820M
totalEquity 48M -70M -589M -555M -737M -892M -1 066M -1 137M -1 250M -1 508M -1 618M -1 934M 4 722M -820M
totalLiabilitiesAndStockholdersEquity 11 891M 12 058M 11 012M 10 979M 10 763M 10 955M 10 437M 10 614M 10 597M 10 681M 11 335M 10 908M 9 642M 10 434M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 11 891M 12 058M 11 012M 10 979M 10 763M 10 955M 10 437M 10 614M 10 597M 10 681M 11 335M 10 908M 9 642M 10 434M
totalInvestments 5 316M -808M 0 -32 000 0 0 0 0 0 0 0 0 0 0
totalDebt 8 714M 8 760M 8 654M 8 730M 8 711M 8 913M 8 699M 8 893M 9 094M 9 134M 9 298M 9 348M 1 520M 0
netDebt 8 139M 8 067M 8 240M 8 404M 8 252M 8 207M 8 200M 8 348M 8 400M 8 397M 8 290M 8 618M 1 379M -500M
link Link Link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2022 q1 2021 q4 2021 q3 2021 q2 2021 q1 2020 q4 2020 q3 2020 q2 2020 q1
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31
symbol OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN OGN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-03 2024-02-26 2023-11-03 2023-08-09 2023-05-05 2023-02-27 2022-11-04 2022-08-05 2022-05-06 2022-03-21 2021-11-12 2021-08-16 2021-06-21 2020-12-31 2020-09-30 2020-06-30 2020-03-31
acceptedDate 2024-05-03 08:10:28 2024-02-26 08:10:46 2023-11-03 07:52:59 2023-08-09 08:39:59 2023-05-04 18:40:01 2023-02-27 07:47:13 2022-11-03 17:58:50 2022-08-04 18:02:03 2022-05-05 21:16:53 2022-03-21 08:27:29 2021-11-12 16:52:11 2021-08-16 08:20:13 2021-06-21 08:16:50 2020-12-30 19:00:00 2020-09-29 20:00:00 2020-06-29 20:00:00 2020-03-30 20:00:00
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000 2022.000 2021.000 2021.000 2021.000 2021.000 2020.000 2020.000 2020.000 2020.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
netIncome 201M 546M 58M 242M 177M 108M 227M 234M 348M 202M 323M 427M 399M 368M 547M 542M 703M
depreciationAndAmortization 65M 60M 61M 58M 57M 52M 57M 50M 53M 62M 52M 43M 38M 50M 40M 34M 33M
deferredIncomeTax 5M -489M 8M -7M 3M 0 -9M -5M -4M -76M -41M -146M -25M -12M 8M 25M -15M
stockBasedCompensation 26M 27M 27M 25M 22M 23M 18M 19M 15M 15M 15M 18M 11M 22M 11M 11M 10M
changeInWorkingCapital -223M 225M 90M -307M -163M 55M 25M -243M -289M -228M -9M 65M 874M 40M -299M 77M -15M
accountsReceivables 163M -27M 6M -230M 39M -4M 6M -179M 54M 99M -4M -332M -40M 286M -147M 176M -156M
inventory 19M -93M -13M -86M -38M -86M -53M -95M 14M -48M -92M 35M -33M -30M 31M -20M -10M
accountsPayables -349M 231M -42M 113M -139M 86M -86M 61M -298M -281M -130M 1 070M 4M 16M 18M -4M -3M
otherWorkingCapital -56M 114M 139M -104M -25M 59M 158M -30M -59M 2M 20M -922M 784M -201M -21M -14M 10M
otherNonCashItems 325M 28M 17M 16M 18M 29M -1 000 000 96M 0 72M 28M 132M 207M -38M -19M 114M -50M
netCashProvidedByOperatingActivities 76M 397M 261M 27M 114M 267M 317M 151M 123M 47M 368M 539M 1 504M 430M 288M 803M 666M
investmentsInPropertyPlantAndEquipment -46M -81M -55M -71M -54M -65M -215M -84M -63M -138M 0 0 0 0 0 0 0
acquisitionsNet -50M -2M 0 0 0 -55M 0 -69M 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites -50M 2M 0 1 000 000 0 59M 2M 70M 0 5M -61M -249M -38M -118M -50M -41M -49M
netCashUsedForInvestingActivites -96M -81M -55M -70M -54M -61M -213M -83M -63M -133M -61M -249M -38M -118M -50M -41M -49M
debtRepayment -2M -2M -2M -82M -252M -2M 0 -104M -2M -102M -10M -946M -566M -79M 0 0 0
commonStockIssued 0 -15M 2M 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStockRepurchased -2M -2M -2M 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid -70M -73M -74M -74M -73M -73M -74M -72M -71M -71M 0 0 0 0 0 0 0
otherFinancingActivites -2M -2M -2M 68M -1 000 000 -7M -3M -7M -18M -14M -8M 1 179M -795M -598M -303M -577M -618M
netCashUsedProvidedByFinancingActivities -74M -77M -78M -88M -326M -82M -77M -183M -91M -187M -18M 233M -1 361M -677M -303M -577M -618M
effectOfForexChangesOnCash -24M 40M -40M -2M 19M 83M -73M -34M -12M 2M -11M 46M -14M 54M 2M -61M 2M
netChangeInCash -118M 279M 88M -133M -247M 207M -46M -149M -43M -271M 278M 589M 71M -677M -303M -577M 0
cashAtEndOfPeriod 575M 693M 414M 326M 459M 706M 499M 545M 694M 737M 1 008M 730M 141M 70M 0 0 0
cashAtBeginningOfPeriod 693M 414M 326M 459M 706M 499M 545M 694M 737M 1 008M 730M 141M 70M 0 0 0 319M
operatingCashFlow 76M 397M 261M 27M 114M 267M 317M 151M 123M 47M 368M 539M 1 504M 430M 288M 803M 666M
capitalExpenditure -46M -81M -55M -71M -54M -65M -215M -84M -63M -138M -253M -59M -38M -144M -47M -47M -40M
freeCashFlow 30M 316M 206M -44M 60M 202M 102M 67M 60M -91M 115M 480M 1 466M 286M 241M 756M 626M
link Link Link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-16 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-05-02 11:30 ET
Organon Reports Results for the First Quarter Ended March 31, 2024
2024-04-08 10:15 ET
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
2024-04-08 10:00 ET
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
2024-02-20 13:00 ET
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
2024-02-15 12:30 ET
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
2024-02-01 12:30 ET
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
2024-01-10 12:33 ET
Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
2024-01-08 12:30 ET
Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
2023-12-21 12:30 ET
Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-18 12:30 ET
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
2023-11-21 12:30 ET
Organon To Present at the Piper Sandler 35th Annual Healthcare Conference
2023-11-07 21:15 ET
Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®
2023-11-02 11:30 ET
Organon Reports Results for the Third Quarter Ended September 30, 2023
2023-11-01 11:30 ET
Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed
2023-10-19 11:30 ET
Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023
2023-09-27 11:30 ET
Organon Recognized on Fortune’s 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice
2023-09-14 21:12 ET
First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology
2023-09-05 14:00 ET
Organon Bolsters Research & Development Expertise with Two Leadership Appointments
2023-08-08 11:30 ET
Organon Reports Results for the Second Quarter Ended June 30, 2023
2023-08-01 11:00 ET
Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar
2023-07-17 11:30 ET
Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023
2023-07-01 10:30 ET
Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
2023-06-27 11:30 ET
Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals
2023-06-07 11:30 ET
Organon and CAF, Development Bank of Latin America, Launch First-of-Its-Kind Collaboration to Increase Sustainable Financing in Women’s Health
2023-05-04 11:30 ET
Organon Reports Results for the First Quarter Ended March 31, 2023
2023-04-20 11:30 ET
Organon To Report First Quarter and Host Conference Call on May 4, 2023
2023-03-07 12:00 ET
Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
2023-02-16 12:30 ET
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2022
2023-02-13 11:43 ET
Ahead of International Women's Day, Organon Calls for Recognition of the Impacts of Underinvesting in Women's Health
2023-02-06 12:30 ET
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023
2023-01-05 12:30 ET
Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
2022-12-15 12:30 ET
Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-12 12:30 ET
Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary
2022-11-15 12:30 ET
Organon To Present at the Piper Sandler 34th Annual Healthcare Conference
2022-11-14 12:40 ET
Organon Announces Formal Commitment to FP2030 To Help Prevent 120 Million Unintended Pregnancies in Low- and Middle-Income Countries Around the World
2022-11-03 11:30 ET
Organon Reports Results for the Third Quarter Ended September 30, 2022
2022-10-20 11:30 ET
Organon To Report Third Quarter Results and Host Conference Call on November 3, 2022
2022-08-17 11:30 ET
Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
2022-08-04 11:30 ET
Organon Reports Results for the Second Quarter Ended June 30, 2022
2022-07-28 11:30 ET
Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
2022-07-21 11:30 ET
Organon To Report Second Quarter Results and Host Conference Call on August 4, 2022
2022-06-13 12:30 ET
Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
2022-06-02 11:00 ET
On One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report
2022-05-05 11:30 ET
Organon Reports Results for the First Quarter Ended March 31, 2022
2022-04-21 11:30 ET
Organon To Report First Quarter Results and Host Conference Call on May 5, 2022
2022-03-31 11:00 ET
Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)
2022-03-02 12:00 ET
Organon To Present at the Cowen 42nd Annual Healthcare Virtual Conference
2022-03-01 11:55 ET
Meghan Rivera Appointed US Managing Director, Organon
2022-02-17 11:30 ET
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2021
2022-02-02 13:05 ET
Organon Launches a Drive to Make International Women’s Day an Annual Holiday to Give Women a Chance to Put Their Health Needs First
2022-02-02 12:00 ET
Organon Declares Paid Time Off for All Employees on International Women’s Day; Employees to Focus on Their Own Health in Recognition of Growing Women’s Health Inequity
2022-02-01 12:30 ET
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 17, 2022
2022-01-05 11:30 ET
FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
2021-12-20 12:30 ET
Organon To Present at the 40th Annual J.P. Morgan Healthcare Virtual Conference
2021-12-13 14:00 ET
Organon Completes Acquisition of Forendo Pharma
2021-11-22 12:30 ET
Organon To Present at the Evercore ISI 4th Annual HealthCONx Conference
2021-11-11 11:31 ET
Organon Reports Results for the Third Quarter Ended September 30, 2021
2021-11-11 11:30 ET
Organon to Acquire Forendo Pharma
2021-10-28 11:30 ET
Organon To Report Third Quarter Results and Host Conference Call on November 11, 2021

SEC forms

Show financial reports only

SEC form 10
2024-05-03 08:10 ET
Organon & Co. published news for 2024 q1
SEC form 10
2024-05-03 00:00 ET
Organon & Co. published news for 2024 q1
SEC form 8
2024-05-02 07:43 ET
Organon & Co. published news for 2024 q1
SEC form 8
2024-05-02 07:43 ET
Organon & Co. reported for 2024 q1
SEC form 8
2024-05-02 07:43 ET
Organon & Co. published news for 2024 q1
SEC form 10
2024-02-26 00:00 ET
Organon & Co. published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Organon & Co. published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Organon & Co. published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Organon & Co. reported for 2023 q4
SEC form 10
2023-11-03 07:52 ET
Organon & Co. published news for 2023 q3
SEC form 10
2023-11-03 00:00 ET
Organon & Co. published news for 2023 q3
SEC form 8
2023-11-02 07:38 ET
Organon & Co. reported for 2023 q3
SEC form 10
2023-08-09 08:39 ET
Organon & Co. published news for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Organon & Co. published news for 2023 q2
SEC form 6
2023-08-08 07:58 ET
Organon & Co. reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Organon & Co. published news for 2023 q2
SEC form 6
2023-07-07 16:05 ET
Organon & Co. published news for 2023 q2
SEC form 6
2023-06-08 17:07 ET
Organon & Co. published news for 2023 q1
SEC form 10
2023-05-04 18:40 ET
Organon & Co. published news for 2023 q1
SEC form 6
2023-05-04 07:50 ET
Organon & Co. published news for 2023 q1